Yesterday, Nov. 10, 2015, 105 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $354.40 to $12,639,826.44.

Highlighted Stocks Traded by Insiders:

TE Connectivity (TEL) - FREE Research Report

Hau Robert W., who is EVP & Chief Financial Officer at TE Connectivity, sold 6,000 shares at $66.02 on Nov. 10, 2015. Following this transaction, the EVP & Chief Financial Officer owned 28,626 shares meaning that the stake was reduced by 17.33% with the 6,000-share transaction.

The shares most recently traded at $65.99, down $0.03, or 0.05% since the insider transaction. Historical insider transactions for TE Connectivity go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 10,360
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 10,360
  • 24-Week # shares bought: 2,100
  • 24-Week # shares sold: 18,849

The average volume for TE Connectivity has been 2.4 million shares per day over the past 30 days. TE Connectivity has a market cap of $26.5 billion and is part of the technology sector and electronics industry. Shares are up 3.56% year-to-date as of the close of trading on Tuesday.

TE Connectivity Ltd., together with its subsidiaries, designs and manufactures connectivity and sensors solutions. It operates through four segments: Transportation Solutions, Industrial Solutions, Network Solutions, and Consumer Solutions. The stock currently has a dividend yield of 2%. The company has a P/E ratio of 21.9. Currently, there are 6 analysts who rate TE Connectivity a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on TEL - FREE

TheStreet Quant Ratings

rates TE Connectivity as a

buy

. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, solid stock price performance and reasonable valuation levels. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

TE Connectivity Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Ocata Therapeutics (OCAT) - FREE Research Report

Lanza Robert, who is Chief Scientific Officer at Ocata Therapeutics, sold 35,000 shares at $8.31 on Nov. 10, 2015. Following this transaction, the Chief Scientific Officer owned 196,509 shares meaning that the stake was reduced by 15.12% with the 35,000-share transaction.

The shares most recently traded at $8.48, up $0.17, or 1.97% since the insider transaction. Historical insider transactions for Ocata Therapeutics go as follows:

  • 12-Week # shares sold: 8,930
  • 24-Week # shares sold: 8,930

The average volume for Ocata Therapeutics has been 460,600 shares per day over the past 30 days. Ocata Therapeutics has a market cap of $188.3 million and is part of the health care sector and drugs industry. Shares are up 38.59% year-to-date as of the close of trading on Tuesday.

Ocata Therapeutics, Inc., a clinical stage biotechnology company, develops and commercializes regenerative ophthalmology therapeutics in the United States. Currently, there are 2 analysts who rate Ocata Therapeutics a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on OCAT - FREE

TheStreet Quant Ratings

rates Ocata Therapeutics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself and weak operating cash flow. Get the full

Ocata Therapeutics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Libbey (LBY) - FREE Research Report

Streeter Stephanie A, who is Chief Executive Officer at Libbey, bought 2,500 shares at $25.35 on Nov. 10, 2015. Following this transaction, the Chief Executive Officer owned 141,644 shares meaning that the stake was boosted by 1.8% with the 2,500-share transaction.

The shares most recently traded at $25.81, up $0.46, or 1.78% since the insider transaction. Historical insider transactions for Libbey go as follows:

  • 4-Week # shares bought: 405
  • 4-Week # shares sold: 4,713
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 4,713
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 4,713

The average volume for Libbey has been 98,100 shares per day over the past 30 days. Libbey has a market cap of $551.3 million and is part of the consumer goods sector and consumer durables industry. Shares are down 18.89% year-to-date as of the close of trading on Tuesday.

Libbey Inc. manufactures and markets glass tableware products worldwide. The stock currently has a dividend yield of 1.74%. The company has a P/E ratio of 10.3. Currently, there are 2 analysts who rate Libbey a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LBY - FREE

TheStreet Quant Ratings

rates Libbey as a

buy

. The company's strengths can be seen in multiple areas, such as its notable return on equity, impressive record of earnings per share growth and compelling growth in net income. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

Libbey Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.